StemCell Therapy

With the recent death of actor Chadwick Boseman, many may be wondering how a seemingly healthy adult is diagnosed with a disease often thought of as illness of older adults. Although colorectal cancer is most often diagnosed in people 50 years or older and incidence rates in this age group are, in fact, declining, the number of adults under 50 diagnosed with colorectal cancer is rising. According to the National Cancer Institute, approximately 5 percent of all new cases of colorectal cancer in the United States are among persons 15 to 39 years old.

African Americansbear a disproportionate burden of cancer. Studies have shown that those who are diagnosed with colorectal cancer at a young age have worse survival outcomes compared to young white patients.

With improvements in prevention, early detection and treatment, there are more than 1.5 million colorectal cancer survivors living in the U.S. Still, an estimated 53,200 people will die this year, making this disease the third most deadly cancer among men and women in the U.S. Approximately 147,950 people will be diagnosed in 2020. Thats one in 23 men and one in 25 women who will develop colon or rectal cancer, the two malignancies that make up colorectal cancer.

At UC San Diego Health, a comprehensive team of medical, surgical and radiation oncologists use the most advanced treatment options, such as laparoscopic surgery and personalized medicine. At Moores Cancer Center, patients can enroll in clinical trials specifically for colorectal cancer.

Oncologists with Moores Cancer Center are available to answer questions about this disease.

###

Follow this link:
Is 43 Too Young for Colon Cancer? UC San Diego Health Experts Available to Talk About Colorectal Cancer - Newswise

Nanotheranostics, integrating diagnostic and therapeutic functions by nanoplatform, exhibits a great potential in precision and personalized medicine, and also raises the requirement on multifunctional nanomaterials in pursuit of both good biocompatibility and high theranostic performances. The emergence of diverse multifunctional nanomaterials and advanced nanotechnologies unprecedentedly simulates the evolution of nanotheranostics, and enables the integration of multimodal imaging and therapeutic functions in a single theranostic nanoparticle for high-efficacy theranostics of diseases. In engineering of theranostic nanoplatforms, biocompatibility and multifunction are two most important factors which need to be considered. Among various nanotheranostics, multimodal imaging-guided photothermal therapy has attracted intensive attention owing to its less invasiveness and lower side effects compared with conventional radiotherapy and chemotherapy.

In a new article published in the Beijing-based National Science Review, scientists in Shenzhen University, China, hypothesize that controllable incorporation of biocompatible Se element into the lattice of Te nanostructures for construction of TeSex nano-alloys could intrinsically tune the inherent cytotoxicity of Te nanomaterials, enhance the biocompatibility of Te nanomaterials and extend their functions for biomedical applications. In this work, a series of TeSex nano-alloys with different Se incorporating proportions are synthesized to investigate their biocompatibility and develop their theranostic functions. It is determined that the toxicity of Te nanomaterials mainly comes from irreversible oxidation stress and intracellular imbalance of organization and energy, which is exterminated by the nano-alloying by incorporating a moderate proportion of Se (x=0.43). The synthesized TeSex nano-alloy exhibits extraordinarily high NIR-II-photothermal conversion efficiency (77.2%), 64Cu coordination and CT contrast capabilities, enabling high-efficacy photothermal therapy of cancer under the guidance of multimodal PT/PA/PET/CT imaging.

Several main advances are achieved. (1) Advanced TeSex nano-alloys are facilely constructed to intrinsically eliminate the inherent toxicity of Te nanomaterials by the moderate incorporation of biocompatible Se. (2) Advanced mechanisms for Te nanomaterial toxification and TeSex alloying detoxification are uncovered. (3) Advanced theranostic performances with ordinarily high NIR-II-photothermal efficiency and multimodal PT/PA/CT/PET imaging capability are achieved by proposed nano-alloying strategy.

See the article here:
Biocompatible TeSex nano-alloys for PT/PA/CT/PET imaging-guided NIR-II-photothermal therapy - Science Codex

SARASOTA, Fla., Sept. 1, 2020 /PRNewswire/ --Transcendent Publishing today announced the release of Male 2.0: Cracking the Code to Limitless Health and Vitality by author Tracy Gapin, MD, FACS. Since its August release, the book has already reached Amazon bestseller status. Dr. Gapin, a men's health and performance expert and member of the American Urological Association, provides a meaningful impact for men's health with this leading-edge approach.

Over the past thirty years, there has been a relentless population-based decline in mens' testosterone levels by over thirty percent. We've also seen a dramatic increase in the incidence of obesity. Over seventy percent of men are either overweight or obese, which is directly tied to energy, productivity, and overall health and performance. This has led to a men's health epidemic for the 159 million men in the United States.

The Male Method described throughout Male 2.0 was developed to help men lose weight, regain energy, optimize their hormones, and regain peak performance. "We need to go beyond testosterone. We need to take an individualized, systems-based approach to optimize men's health, performance and longevity," says Tracy Gapin, MD, FACS. "Driven by the power of epigenetics, genetics, peptides, and wearable technologies, we have gained incredible insight into some of the most misunderstood aspects of men's health and longevity."

JJ Virgin, New York Times Bestselling author of The Virgin Diet & Sugar Impact Diet said, "As a thought leader in men's health, Dr. Gapin has provided the modern-day blueprint to help men optimize their health and regain their vitality. Every man should read this book."

Clete Walker, CEO of Vituro Health, a prostate health company, said, "Male 2.0 is a revolution for men's health. After my father was diagnosed with prostate cancer, I made it my mission to seek out potential new modalities, and this data-driven approach is the future."

Male 2.0: Cracking the Code to Limitless Health and Vitalityis available on Amazon and during the month of September the print version is available for free at The Gapin Institute. http://www.GapinInstitute.com

About Tracy Gapin, MD FACS:Dr. Gapin is board-certified Urologist, world renowned Men's Health & Performance Expert, Author, and Professional Speaker. Using state-of-the-art biometric monitoring, nutrition and lifestyle intervention, Dr. Gapin coaches Fortune 500 executives and evolutionary leaders of business, sports medicine, and high performance. He specializes in cutting-edge precision medicine with an emphasis on epigenetics, providing men with a personalized path to optimizing health & performance. http://www.GapinInstitute.comEmail: [emailprotected]

About Transcendent Publishing:Since 2012, Transcendent Publishing has specialized in offering a variety of publishing and design services for today's indie author. http://www.transcendentpublishing.com

CONTACT:Leann Spofford[emailprotected]Tel: (941) 524-4592

SOURCE Gapin Institute

Home – MMG

See the article here:
Men's Health Expert Tracy Gapin, MD Unveils Male 2.0 with a Revolutionary Protocol to Conquer the Men's Health Epidemic - PRNewswire

A postdoctoral position is available at the Faculty of Medicine, University of Helsinki, Finland to work in the research group of Dr. Jing Tang (https://www.helsinki.fi/en/researchgroups/network-pharmacology-for-preci...). The position is part of an Academy of Finlands research project that aims to do network pharmacology modeling to provide the mechanism of action of drugs and drug combinations for a systems-level understanding of cancer. The Tang group combines computational methods to offer improved efficiency methods to identify more effective cancer treatments for personalized medicine. The Tang laboratory is based at Research Program in Systems Oncology (ONCOSYS) (https://www.helsinki.fi/en/researchgroups/research-program-in-systems-on...) at the Meilahti biomedical campus.

Role description:

We are seeking at least one postdoctoral researcher to work on the computational methods to develop network pharmacology models for predicting drug combinations. The project is focused on strategies for predicting potential drug combination and patient subclasses by constructing multipartite networks using drug response data. The primary goal of the project is to analyse drug sensitivity datasets to exploit drug-target interaction data to explore the biological mechanism of drugs. A key aim of the work is to propose drug combination regimens focusing on patient-derived drug response data along with the providing a biochemical and biophysical understanding of a drug combination. Hematological malignances and ovarian cancer are the available datasets for this project. The post holder will be responsible for planning and conducting computational research within the project under the supervision of Dr. Mohieddin Jafari, and Prof. Jing Tang.

The ability to work well within a collaborative team is critical for this position. You will work with unique datasets derived from large-scale experiments associated with a diverse range of projects in pharmacology and molecular biology. Salary will be commensurate with qualifications and experience based on the University guidelines. The full-time position start Jan 2021. A six-month trial period will be applied.

Key requirements:

We are seeking a creative and highly motivated individual with primary interest in network science and biomedical data mining. Candidates should have a PhD in bioinformatics, computational biology, statistics, computer science or other related disciplines. The ideal candidate will have experience in at least one of the aforementioned areas, and a strong interest in the others. Previous experience with biological networks, omics datasets, and expertise in related statistics and modelling are considered an advantage. Solid skills in scripting/programming (preferably R and Python) are essential prerequisites for this position. Excellent communication and presentation skills in English, good organisational skills, troubleshooting expertise and the ability to work effectively to tight deadlines are desirable.

Appointment details:

The position is available from October 2020 onwards, and can be started later upon agreement. It is a two-year fixed-term position, with a possibility of extension. Trial period of 6 months will be applied. The salary will be based on level 5 of the demands level chart for teaching and research personnel in the salary system of Finnish universities. In addition, the appointee will be paid a salary component based on personal performance with the overall starting salary amounting to approximately 3300-3600 EUR per month, depending on the qualifications and previous relevant research experience of the candidate.

Application details:

Please submit your application via the University of Helsinki Recruitment System by clicking the Apply for the position button below. Internal applicants (i.e. current employees of the University of Helsinki) should submit their applications through the SAP HR portal. If you need support with the recruitment system, please contact recruitment@helsinki.fi.

Please attach the following documents to your application as a single PDF file:

The deadline for applications is September 30th 2020. Interviews will be conducted either in person or online. For more information on the position, please contact Dr. Mohieddin Jafari (mohieddin.jafari(at)helsinki.fi) and Prof. Jing Tang (jing.tang(at)helsinki.fi).

The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.

Together with the Helsinki University Hospital (HUS) and the Helsinki Institute of Life Sciences (HiLIFE), the Faculty of Medicine, University of Helsinki, constitutes the Academic Medical Center Helsinki (AMCH). This medical center has been very successful in international comparisons, ranking among the top 10 medical campuses in Europe and among the top 50 globally.

Research Program in Systems Oncology (ONCOSYS) consists of basic, translational and clinical researchers who use cutting-edge measurement technology, patient data and AI methods in cancer research and oncology. The overall objective of ONCOSYS is to understand the underlying causes of cancer progression or treatment resistance, and to develop effective diagnostic, prognostic and therapeutic approaches.

Due date

30.09.2020 23:59 EEST

Read the original:
Postdoctoral Researcher in Biological Network Modelling job with UNIVERSITY OF HELSINKI | 223494 - Times Higher Education (THE)

West Palm Beach, FL, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Medical Practice Income (MPI), a subsidiary of USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce the early success of the QHSLab launch in South Florida. Since launching the platform on June 30, 2020, 159 medical practices have provided 374 allergy patients with a QHSLab-generated allergen immunotherapy prescription, generating an estimated $664,608 in reimbursement revenue to these physicians practices.

There are over 450,000 primary care physicians, including licensed nurse practitioners, in the United States. Many are reporting higher rates of fatigue and burnout due to long hours, heavy patient caseloads, and declining practice revenue from a lack of healthcare reimbursements. Primary care physicians are particularly overwhelmed by the number of patients suffering from allergies, which often signal other health related and immune compromising concerns. Doctors need smart, digital medicine solutions that save time and money, while delivering the right treatment to patients that need it. With the addition of QHSLab, not only will physicians be better equipped to treat patients, but they will also be able to sustain their practices with ongoing revenue through healthcare reimbursements, generating new income per practice, per year.

Allergies alone are estimated to affect 1 in every 5 Americans and costs upwards of $18 billion in direct health and medical expenditures annually. It not only impairs quality of life, but is responsible for as much as $4 billion annually in lost productivity due to work and school absences. When over-the-counter allergy medication treatment is no longer successful, allergen immunotherapy is recommended. Allergen immunotherapy is usually prepared by allergy specialists however, today there is a published shortage of board-certified allergy specialists available to treat the number of allergy sufferers.1 Patients must now rely on their primary care provider to effectively manage their allergies. Through our AI-enhanced, physician-directed platform, MPIs QHSLab, were increasing the primary care physicians ability to effectively address their patients chronic conditions, while saving them time and potentially expensive visits to a specialist when not absolutely necessary, said Troy Grogan, President and CEO of Medical Practice Income, Inc and USA Equities Corp.

The Fall of 2020 is soon upon us, but this season will be even more alarming than usual due to the ongoing spread and impact of COVID-19. Fredric Pullen MD, FACS, an Allergy and Ear, Nose & Throat Specialist based in Palm Beach Gardens, FL shared the following insight regarding QHSLab: Its so much easier for busy primary care physicians to have a software system that can automatically generate the patients allergy formulas for their appropriate immunotherapy, based on their allergy test results. It saves time and potential error which is a definite plus for non-allergy specialist doctors, especially in the age of COVID-19.

For more information about Medical Practice Income, or to become a participating physician, please visit https://www.medicalpracticeincome.com/opportunities.

About USA Equities Corp (OTC Link: USAQ)

On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Companys intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit http://www.MedicalPracticeIncome.com/discover.

Forward-Looking Statements

This press release contains forward-looking statements which are identified by words such as may, could, believes, estimates, targets, expects, or intends and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the Risk Factors section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.

Read more from the original source:
Medical Practice Income, Inc., a Subsidiary of USA Equities Corp. (USAQ), Announces the Early Success of QHSLab Launch in South Florida -...

SAN FRANCISCO, Aug. 31, 2020 /PRNewswire/ -- The global lab supplies marketsize is expected to reach USD 49.6 billion by 2027, expanding at a CAGR of7.1%,according to a new report by Grand View Research, Inc. Focus on R&D drives the demand for lab equipment market, thereby boosting the market growth.

In June 2019, the D.O.D's Defense Logistics Agency settled the bidding process for USD 312.0 million contracts, for lab equipment and supplies. There are instances of huge government spending in the category including White House's budget of 2020 that provides USD 134.0 billion for federal R&D, including significant investments in R&D facilities and equipment.

Key suggestions from the report:

Read 120 page research report with ToC on "Lab Supplies Market Size, Share & Trends Analysis Report By Product (Equipment (Autoclaves & Sterilizers, Lab Air Filtration System), Disposables (Tubes, Gloves)), By Region, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/laboratory-supply-market

Laboratories have emerged as multipurpose research facilities in which various types of testing mechanisms, research analogies, and novel developments are carried out. This has also led to an increase in the demand for lab equipment and supplies market. Furthermore, the trend of research-based studies has been gaining traction over the past decade. This has resulted in the development of new laboratories in academic institutes, thereby boosting the market growth.

Recently, clinical laboratories have also gone through major technological advancements. With intense R&D going in the field of the pathogenesis of diseases and personalized medicine, advanced diagnostics methods and tests are being implemented extensively. Technological improvements in instrumentation continue to bring real benefits that accrue from greater ease of use, increased capacity, speed of analysis, higher precision, operational efficiencies, enhanced reliability, improved safety, and numerous other intangibles.

Grand View Research has segmented the global lab supplies market based on product and region:

Find more research reports on Medical Devices Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web:https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Follow this link:
Lab Supplies Market Size Worth $49.6 Billion By 2027 | CAGR: 7.1%: Grand View Research, Inc. - PRNewswire

Patients across the Valley will soon feel more connected to their healthcare providers thanks to a mobile app changing the way clinical documentation and data entry are performed. Bayless Integrated Healthcare, an Arizona leader in integrating mental and physical health, has announced a partnership with Seattle-based healthcare technology company, Saykara, to implement this new technology in its eight locations across the Phoenix area.

The amount of data entry providers must do is on the rise due to additional requirements from insurance companies and government agencies. During a typical appointment, providers must simultaneously converse with patients while filling out electronic health records on a computer, which creates the feeling that providers are disengaged and multi-tasking, rather than offering their full attention. The data entry workload can be so great that providers often bring it home to complete during evening hours, contributing to fatigue and burnout.

The technology from Saykara reverses this trend by utilizing artificial intelligence to automate the challenging and time-consuming aspects of clinical documentation. This frees providers from their computers and restores quality facetime with patients.

Whole person wellness defines everything that we do at Bayless, says President and CEO of Bayless Integrated Healthcare, Justin Bayless. We know that the patient/provider connection is a deeply important part of that equation, and we continuously invest in the tools and technologies to improve that relationship. The more our patients feel heard during their appointments, and the more focused our providers are on them rather than data entry, the better our delivery of personalized medicine and the better our patient outcomes.

At the start of an appointment and with the patients consent, the Bayless provider simply accesses the Saykara mobile app from their iPhone. As the provider and patient engage, the app interprets the conversation and translates it to the data required for the electronic health record, reducing administrative busywork down to mere minutes, rather than hours.

Nobody wants to feel like theyre taking a back seat to administrative busywork when visiting a healthcare provider. This is when were all at our most vulnerable, says President and COO of Saykara, Graham Hughes, MD. By automating clinical documentation, our technology helps ensure that the time shared between a patient and provider is undistracted and that a trusting bond is forged.

The introduction of this technology at Bayless comes at a time when healthcare providers are increasingly reporting burnout amid the COVID-19 pandemic and may help alleviate some of the pressures they face. The result is reduced fatigue in providers, increased facetime with patients and a more trusting and deeply connected relationship between providers and the people in their care.

See the article here:
Bayless Integrated Healthcare deploys AI to improve patient care - AZ Big Media

Background:Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available.

Methods:The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study.

Discussion:This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System.

Trial registration:ClincalTrials.govNCT04147026. Registered on 31 October, 2019.

Keywords:Anti-TNF agents; Personalized medicine; Prediction models; Rheumatoid arthritis.

View original post here:
Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response...

~Program to Focus on Advances and Breakthroughs in MS Research, Diagnostics and Technology~

~Special Press Events Planned to Give Media Access to Key Leaders & Late Breaker Investigators~

MIDDLETON, Wis., Aug. 31, 2020 /PRNewswire/ -- The 8th Joint ACTRIMS-ECTRIMS Meeting, the largest international conference focused on Multiple Sclerosis (MS) research, will be held in a virtual format from September 11-13, 2020, with a special encore session featuring Late-Breaking News and a COVID-19 Session on September 26.

At this virtual conference MSVirtual2020 world class scientists, neurologists, clinicians and researchers from around the world will be presenting the latest research, clinical trial outcomes and technology and diagnostic advances in multiple sclerosis (MS).

Media registration, which is open to editors, reporters, producers, and active freelance writers and bloggers, will allow access to the full program including plenary sessions, invited speakers and platform presentations. Press Registration can be completed online here, or to expedite press registration, you can send a request directly to the Press Managers. They can be reached at: [emailprotected]and [emailprotected]. They are also available to arrange interviews with participating leaders, presenters and experts that you may wish to connect with.

The MSVirtual2020 program at a glance can be found here. Key topics will cover:

Keynote speakers will include:

MSVirtual2020 will be hosting a Newsroom on Newswise that will house various media materials including press releases, videos, infographics, bios & photos of leaders and speakers, and other assets. Newswise will also host a few Zoom press events for media only that will allow registered journalists to access and ask live questions to ACTRIMS-ECTRIMS leaders and late breaking investigators. The link to the MSVirtual2020 Newsroom is: here, or at the following link: https://www.newswise.com/home/actrims. The conference hashtag is: #MSVirtual2020.

MSVirtual2020 Press Events:

SOURCE Americas Committee for Treatment and Research in Multiple Sclerosis

Read more here:
The 8th Joint ACTRIMS-ECTRIMS Meeting - MSVirtual2020 - To be Held September 11-13 With A Special Encore Session Featuring COVID-19 & MS and Late...

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Peloton (NASDAQ: PTON), the world's largest interactive fitness platform, today announced the formation of the Peloton Health and Wellness Advisory Council, which will work closely with the company as it continues to look at how it can positively impact the physical, mental and emotional wellbeing of its community of Members from around the world. Peloton will collaborate with the council, which includes five renowned doctors, researchers and other medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience, and draw on their knowledge and expertise to help inform product and content development, community-focused and social impact initiatives, research projects and more.

"We constantly hear from our Members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression," said William Lynch, president, Peloton. "With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform."

The Peloton Health and Wellness Advisory Council includes the following experts:

Cardiovascular MedicineSuzanne Steinbaum, MD:Dr. Suzanne Steinbaum is an attending cardiologist, specializing in prevention. She has recently opened a private practice in New York City, at the Juhi-Ash integrative health center encompassing heart health, wellness and prevention, as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a personalized lifestyle management program using anatomy, physiology, functional data, genetics and metabolism, along with technology to reach ultimate cardiovascular health. She has been the Director of Women's Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Women's Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Women's Heart Alliance.

NeurologyRichard S. Isaacson, MD:Richard S. Isaacson, M.D. is a Neurologist, clinician and researcher who specializes in Alzheimer's prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimer's disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimer's Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimer's disease, Journal of Communication in Healthcare, Alzheimer's & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Vernon Williams, MD:Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, CA. Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commission's Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty: Sports Neurology and Pain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Cardiopulmonary ExerciseAimee M. Layton, PhD:Aimee Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center / New York Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being director of the adult pulmonary exercise laboratory for a decade. This cross discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Layton's prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids' behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

NeuroscienceJay Alberts, PhD:As a Cleveland Clinic Scientist, Ph.D., Jay Alberts' research is aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinson's disease, stroke, Alzheimer's and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinson's disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer reviewed articles, has had uninterrupted extramural funding since 1999 and holds 10 patents.

For more information about Peloton or the Peloton Health and Wellness Advisory Council, please visit http://www.blog.onepeloton.com.

About PelotonPeloton is the largest interactive fitness platform in the world with a loyal community of more than 2.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. Peloton makes fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage its Members to be the best versions of themselves. An innovator at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry by developing a first-of-its-kind subscription platform that seamlessly combines the best equipment, proprietary networked software, and world-class streaming digital fitness and wellness content, creating a product that its Members love. The brand's immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which allows access to a full slate of fitness classes across disciplines, on any iOS or Android device, Apple TV, Fire TV, Roku TVs, and Chromecast and Android TV. Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit http://www.onepeloton.com.

SOURCE Peloton

http://www.pelotoncycle.com

More:
Peloton Introduces Its First-Ever Health And Wellness Advisory Council - PRNewswire

EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor Conference, on Wednesday, September 02, 2020 3:40 PM Eastern Time.

A live webcast of the presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2019/36691. The webcast will be archived for 90 days following the live presentation.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.Predictive-Oncology.com.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate,” believe,” estimate,” expect,” intend,” may,” plan,” would,” target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

Read the original post:
Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time...

Precision Medicine Market Trends, In-Depth Research on Market Size, Emerging Growth Factors, Global 2020 Trends and Forecasts 2025

The Precision MedicineMarket report is one of the most comprehensive and important dataabout business strategies, qualitative and quantitative analysis of Global Market.It offers detailed research and analysis of key aspects of the Precision Medicinemarket. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Precision Medicinemarket.

The researchers have considered almost all important parameters for company profiling, including market share, recent development, gross margin, future development plans, product portfolio, production, and revenue. The report includes detailed analysis of the vendor landscape and thorough company profiling of leading players of the Precision Medicine market.

Get PDF sample copy of this report(Including impact of Covid-19)@: https://www.marketinforeports.com/Market-Reports/Request-Sample/161616

Top Leading players covered in the Precision Medicine market report: Johnson & Johnson, IBM, GE Healthcare, Illumina, Roche, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Novartis, Abbott Laboratories, Almac Group, Intel Corporation, Biomrieux Sa, Cepheid, Qiagen, Randox Laboratories, Healthcore and More

Key Types:DiagnosticsTherapies

Key End-Use:OncologyNeurosciencesImmunologyRespiratoryOthers

The global Precision Medicine market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, South America, Middle East and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

The latest report added by Market Info Reportsdemonstrates that the global Precision Medicine market will showcase a steady CAGR in the coming years. The research report includes a thorough analysis of market drivers, restraints, threats, and opportunities. It addresses the lucrative investment options for the players in the coming years. Analysts have offered market estimates at a global and regional level.

Major Points Covered in TOC:

Overview: Along with a broad overview of the global Precision Medicine market, this section gives an overview of the report to give an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain competitive advantage over their competitors in the Precision Medicine market.

Study on Key Market Trends: This section of the report offers deeper analysis of latest and future trends of the Precision Medicine market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Precision Medicine market.

Regional Growth Analysis: All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Precision Medicine market. Market participants can use this analysis to make strategic investments in key growth pockets of the Precision Medicine market.

For More Information:https://www.marketinforeports.com/Market-Reports/161616/Precision-Medicine-market

The study objectives are:

Customization of the Report:

Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/161616/Precision-Medicine-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]

Original post:
Precision Medicine Market Analysis By Distribution Channel, Region And Forecast From 2020 To 2025|Johnson & Johnson, IBM, GE Healthcare, Illumina,...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Looking for more? Check out our repository for all available reports on Precision Medicine in related sectors.

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Precision Medicine Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The Scarlet

Abstract

With the onset of the Human Genome Project, social concerns about 'genetic information discrimination' have been raised, but the problem has not yet been highlighted in Korea. However, non-medical institutions' genetic testing which is related to disease prevention could be partially allowed under the revised "Bioethics and Safety Act" from June 30, 2016. In the case of one domestic insurance company, DTC genetic testing was provided for the new customer of cancer insurance as a complimentary service, which made the social changes related to the recognition of the genetic testing. At a time when precision medicine is becoming a new standard for medical care, discipline on genetic information discrimination has become a problem that can not be delayed anymore. Article 46 and 67 of the Bioethics Act stipulate the prohibition of discrimination on grounds of genetic information and penalties for its violation. However, these broad principles alone can not solve the problems in specific genetic information utilization areas such as insurance and employment. The United States, Canada, the United Kingdom, and Germany have different regulations that prohibit genetic information based discrimination. In the United States, Genetic Information Non-Discrimination Act takes a form that adds to the existing law about the prohibition of genetic information discrimination. In addition, the range of genetic information includes the results of genetic tests of individuals and their families, including "family history". Canada has recently enacted legislation in 2017, expanding coverage to general transactions of goods or services in addition to insurance and employment. The United Kingdom deals only with 'predictive genetic testing results of individuals'. In the case of insurance, the UK government and Association of British Insurers (ABI) agree to abide by a policy framework ('Concordat') for cooperation that provides that insurers' use of genetic information is transparent, fair and subject to regular reviews; and remain committed to the voluntary Moratorium on insurers' use of predictive genetic test results until 1 November 2019, and a review of the Concordat in 2016. In the case of employment, The ICO's 'Employment Practices Code (2011)' is used as a guideline. In Germany, Human Genetic Examination Act(Gesetz ${ddot{u}}ber$ genetische Untersuchungen bei Menschen) stipulates a principle ban on the demand for genetic testing and the submission of results in employment and insurance. The evaluation of the effectiveness of regulatory framework, as well as the form and scope of the discipline is different from country to country. In light of this, it would be desirable for the issue of genetic information discrimination in Korea to be addressed based on the review of related regulations, the participation of experts, and the cooperation of stakeholders.

Read more:
Legal and Regulatory Issues in Genetic Information ...

Interpretation of genetic test results

It is important that cytogenetic and molecular genetic test results are correctly interpreted to ensure that patients receive accurate information about their risks, particularly where different mutations in the same gene may result in a different phenotype, risk or the need for a particular type of follow-up.

New generation tests may not only identify mutations in genes which we expect or predict to find in a patient, but also other changes which may be more difficult to interpret. Careful thought has to go into whether or not patients or prospective parents are informed of these findings. This can create a very difficult situation for healthcare professionals, where there may be no way of knowing the significance of the finding. It is possible that the incidental finding is a variation of normal and therefore of no consequence to the patient.

On the other hand, the genetic change may be of significance, in which case patients may need to be told that a change has been observed, but with no information to inform them of what this might mean. This could be particularly difficult in prenatal testing where any concern raised about the foetus genome is likely to cause a great deal of anxiety.

With new genome sequencing it is hoped that medical care will become more personalised, allowing earlier and more accurate diagnosis to be made and better care to those with conditions like cancer. It is hoped that treatment will be more effective as it will be individualised for the patient's needs and the use of specific medication and their dosages will be tailored to the particular patient. This will all depend, of course, on the correct interpretation of results.

It is obviously a patient's choice as to whether they want to have genetic testing done. Whether or not it is offered may depend on their risk, and of course that the risk is identified at the outset. A patient may have an increased risk of a particular condition for a number of reasons, including their family history, environmental factors or their age.

A claim for clinical negligence could arise where a risk has not been identified and testing or screening not offered, and that patient suffers as a consequence. For example, a female patient presenting in early pregnancy may disclose a strong family history of mental retardation. If the clinician is not alert to this, the offer of appropriate referral to genetics services and testing for mental retardation syndromes (such as Fragile X syndrome) will not be made available to the patient.

This is clearly a problem that can arise for any type of test, not just results of genetic tests. A patient may come to harm where results are requested but not returned, or returned and not acted upon. It is important that there are robust systems in place to ensure that when a test is requested, it is followed up appropriately and any necessary action taken in a timely manner.

Failing to advise patients of the outcome of genetic tests may result in them missing out on vital preventative screening or being offered the option of prophylactic surgery. Similarly, prospective parents may go ahead with their plans to start a family, unaware of the fact that there is a risk of an inherited genetic condition in their offspring.

Where prenatal testing has taken place, there is the possibility of claims arising from misinterpretation of results or the failure to offer testing where appropriate. 'Wrongful birth' claims arise where a prospective mother is not advised of a condition that might affect a future pregnancy, or may be affecting her current pregnancy, and therefore is not given the option of deciding whether to conceive or to continue her pregnancy. If a child is subsequently born with a disability as a result of the condition, a claim may be pursued.

Genetic and genomic medicine is a constantly changing and developing field. As patient care becomes more personalised - with pharmacogenetics, for example, where medications are prescribed based on a patient's individual genome - there is the potential for more medico-legal and ethical questions to be raised. The MDU will continue to assist members in managing any risks as they arise.

Medico-legal adviser

BSc (Hons) MBChB (Hons) LLB MA MRCPCH FFFLM DMedEth

Kathryn has been a medico-legal adviser with the MDU since 2007 and is a team leader, trainer and mentor in the medical advisory department. Before joining the MDU, she worked in paediatrics gaining her MRCPCH in 2002 and did her specialty training in clinical genetics. She has an MA in Health Care Ethics and Law, a Bachelor of Law and a Professional Doctorate in Medical Ethics. She is also a fellow of the Faculty of Forensic and Legal Medicine and has previously been an examiner and Deputy Chief Examiner for the faculty exam. Kathryn is currently a member of the faculty's Training and Education Subcommittee.

Link:
The legal aspects of genetic testing - Medical Defence Union

August 26, 2020

Food and Drug Administration Commissioner Steven Hahn, having been battered around for his egregiously inaccurate endorsement Sunday of a purported COVID-19 treatment pushed by President Donald Trump, walked that endorsement back Monday and Tuesday.

It isnt enough. Hahn has damaged his credibility, possibly beyond repair, and taken the credibility of the FDA down with him at a crucial moment when the agencys trustworthiness may be more important than at any time in its 114-year history.

He has behaved like a Trump sycophant rather than the head of an independent, science-based arm of the federal government, and for that he has to go.

I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma, Hahn tweeted Monday, at the start of an apology round that also took him to CBS This Morning. The criticism is entirely justified, he tweeted. What I should have said better is that the data show a relative risk reduction, not an absolute risk reduction.

On CBS, he said, I could have done a better job and should have done a better job at that press conference explaining what the data show.

Lets take a closer look at what this is all about, and why Hahns most recent statements are insufficient.

The issue involved convalescent plasma, which is blood fluid taken from patients who have recovered from COVID-19. Its then transfused into new COVID-19 patients, with the aim of allowing antibodies the original patients developed during their illness to fight the infection in the new patients.

Sundays White House press conference was called to announce that the FDA had issued an emergency use authorization for convalescent plasma in COVID-19 cases. This move isnt tantamount to FDA clinical approval and has little practical effect, since researchers already were using the substance in clinical trials.

But it does raise the possibility that the general public will think that the FDA has concluded that it works for COVID-19 patients, for which there is still no evidence.

In short, the FDAs announcement benefited no patients or researchers. It smacked of being timed to coincide with the start of the Republican National Convention, which opened Monday with Trumps renomination. Hahn denies that the timing was anything but coincidental.

Convalescent plasma has been used for about 100 years as treatment for other diseases. It has never been a miracle drug or a breakthrough, as Trump has described it. Though researchers have seen some evidence that it may help seriously ill COVID-19 patients, medical experts strongly doubt that it will be a breakthrough drug now.

That brings us to Hahns original error.

As I reported, at a White House press conference Sunday, Hahn stated in Trumps presence that for patients treated with convalescent plasma there was a 35% improvement in survival, which he called a significant clinical benefit. He tried to explain what he meant by adding that, of 100 people who are sick with COVID-19, 35 would have been saved because of the administration of plasma.

None of that is true. The Mayo Clinic study on which his remarks were based says nothing of the kind. It says that preliminary results from its trial show that patients given convalescent plasma with a high concentration of antibodies and receive it within three days of diagnosis with COVID-19 have a 35% better survival rate than those given plasma with a low concentration of antibodies and who receive it four days or more after diagnosis.

The best one could say is that five out of 100 people in the trial but really only three out of 100 would have better survival rates. Even that conclusion is dubious, however, because the Mayo study doesnt compare the patients who received plasma to those who didnt receive it at all it merely compares those who receive different versions of the plasma and on different schedules to each other.

From that, its impossible to tell what benefit convalescent plasma has on COVID-19 patients, if any. Two studies, in China and the Netherlands, that actually tested convalescent plasma against a placebo were both ended early because of safety concerns. But neither showed any positive effect before they were curtailed.

Hahns statement instantly drew a pushback from medical experts. Jonathan Reiner of George Washington University medical school called it shockingly wrong. Eric Topol, head of the Scripps Research Translational Institute in La Jolla, California, called it not only blatantly wrong (but) an egregious public statement.

Hahns original statement was so profoundly wrong that his walkback Monday and Tuesday cant help but increase public confusion.

This is just blatantly wrong and misleading to the public, Topol told me. Millions of people now think that this is a breakthrough miracle treatment, but theres no data to support that. He has to say that there has been no survival advantage established for convalescent plasma, period, stop.

Hahns apology doesnt help, because its couched in technical language. The public doesnt understand the nuances of relative and absolute risk. Until he says that there is no survival advantage established, the public wont get it, Topol says. And he has to say it in public not through Twitter, and not through an exclusive CBS This Morning interview.

As for that interview, Hahn didnt err on Sunday by doing a bad job explaining the data. He completely misrepresented the data. On CBS he described the Mayo Clinic data in a way that was so confusing and incomplete that the lay viewer could still come away with the impression that theres solid evidence for plasmas positive effect. Thats completely unacceptable.

Of the FDAs emergency use authorization, Hahn told Gayle King of the CBS program, I can assure the American people that this decision was made based upon sound science and data.

Can that assurance be taken at face value? Unfortunately, no.

The importance of the FDAs credibility at this moment cant be overstated. At some point within the next year, the agency will be called on to validate the safety and efficacy of any vaccines for COVID-19 that emerge from clinical testing.

In an era in which conspiracy theories animate resistance even to vaccines of proven safety and efficacy, doubts about a new vaccine against a novel disease will threaten public health if they prompt people to refuse immunization. By appearing to truckle to Trumps political demands, Hahn is making it impossible to trust the FDAs judgment on COVID-19 vaccines.

Thats tragedy in the making. Hahns performance this weekend started out shamefully, and has only gotten worse.

See the article here:
Their view: Now is not the time to legalize marijuana - Wilkes Barre Times-Leader

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis (RA) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted RA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Rheumatoid Arthritis (RA) Understanding

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease that is known to impact the joints of the body adversely. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body, on the onset of disease, the immune response primarily attacks and harm the joints. RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

Clinically, the symptoms of RA significantly differ between early-stage RA and insufficiently treated later stages of the disease. Early-stage RA is characterized by generalized disease symptoms such as fatigue, flu-like feeling, swollen and tender joints, and morning stiffness; and is paralleled by elevated levels of C-reactive protein (CRP) and an increased erythrocyte sedimentation rate (ESR). In contrast, insufficiently treated RA displays a complex clinical picture with the occurrence of serious systemic manifestations such as pleural effusions, lung nodules and interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, keratoconjunctivitis, atherosclerosis, hematologic abnormalities (e.g., anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint misalignments, loss of range of motion, bone erosion, cartilage destruction, and rheumatic nodules. These systemic manifestations caused by the chronic inflammatory state in RA patients result in increased mortality.

Rheumatoid Arthritis Diagnosis

Typically, RA is diagnosed by a combination of patient's symptoms, results of doctors examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.

More than two thirds of RA patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.

Epidemiology Perspective

The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA, Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- RA Epidemiology

Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.

Reasons to buy

Key Assessments

Geographies Covered

Study Period: 2017-2030

For more information about this report visit https://www.researchandmarkets.com/r/fxpicl

Read the original:
Insights into the Rheumatoid Arthritis Industry to 2030 - Develop Business Strategies by Understanding Trends - ResearchAndMarkets.com - Business Wire

Most adults with systemic lupus erythematosus (SLE) are not at increased risk of hospitalization from 2019 coronavirus disease (COVID-19) due to medications used to dampen their altered immune system, the cause of the disease. Nor are most people with more common types of arthritis, such as rheumatoid, psoriatic, and spondyloarthritis, at greater risk of hospitalization from COVID-19, a pair of new reports shows.

SLE, known widely as lupus, along with common forms of arthritis are autoimmune conditions caused by the immune systems mistaken attack on a persons own tissues, leading to inflammation in the joints, skin, kidneys, and other parts of the body. The majority of those affected by these diseases are women.

Although the new studies, led by NYU Grossman School of Medicine researchers, show that for some of those affected the use of steroid medications to reduce inflammation slightly increased the likelihood of needing hospital care, researchers say the results should be reassuring to patients overall.

Many people are taking steroids or other immunosuppressing medications, especially newer biologic drugs, to prevent their immune systems attack on their tissues. And the researchers say their patients report feeling added anxiety that their treatments make them more susceptible to the dangers of coronavirus infection.

In the first study, published recently in the journal Arthritis and Rheumatology, researchers closely monitored the health of 226 adult patients, mostly Black, Hispanic, and female, receiving treatment at NYU Langone Health clinics or NYC Health + Hospitals/Bellevue for mild to severe forms of lupus. All were surveyed by phone or email, or had their medical records checked between April 13 and June 1, when the pandemic peaked in the New York City region. Twenty-four were hospitalized out of 41 who were formally diagnosed with COVID-19, and 4 of them died. Another 42 had COVID-19like symptoms but were not formally tested.

For the second study, also published in Arthritis and Rheumatology, researchers monitored 103 mostly white women being treated at NYU Langone Health clinics between March 3 and May 4 for inflammatory arthritis, which unlike common osteoarthritis, does not primarily result from joint wear and tear. All tested positive for COVID-19 or had symptoms highly suggesting they were infected. Twenty-seven (26 percent) were hospitalized, with 4 deaths (4 percent).

Researchers say their latest study findings showed that patients with lupus taking immune-suppressing medications, such as mycophenolate mofetil (CellCept) and azathioprine (Imuran), had no greater risk of hospitalization (15 out of 24) than patients with lupus not using the medications (9 of 17). Similarly, hospitalization rates for people with inflammatory arthritis (26 percent) and COVID-19 were also no greater than seen for all New Yorkers (25 percent, according to city figures).

Among the research teams other findings was that patients taking biologic drugs for arthritis, such as adalimumab (Humira) and etanercept (Enbrel), which are made from living cells, or the antiviral hydroxychloroquine, were at no greater or lesser risk of hospitalization than those not taking the drugs. However, those taking glucocorticoids, a type of steroid, even in mild doses, were upwards of 10 times more likely to be hospitalized than patients with arthritis not using steroids. The researchers caution that although statistically significant, the studys small size may overestimate the actual risk.

Our findings represent the largest of its kind for American patients with lupus or arthritis and COVID-19, and should reassure most patients, especially those on immunosuppressant therapy, that they are at no greater risk of having to be admitted to hospital from COVID-19 than other lupus or arthritis patients, says one of the studies co-lead investigators, Ruth Fernandez-Ruiz, MD.

People with lupus or inflammatory arthritis have the same risk factors for getting seriously ill from COVID-19 as people without these disorders, says Dr. Fernandez-Ruiz, a postdoctoral fellow in rheumatology in the Department of Medicine at NYU Langone.

These shared risk factors, she says, which overall more than double peoples risk of hospitalization from COVID-19, are having multiple underlying health conditions, such as obesity, hypertension, and diabetes.

Patients receiving therapy for lupus and inflammatory arthritis should not automatically stop taking their medications for fear that they would be worse off if they also caught the coronavirus, says another of the studies co-lead investigators, Rebecca Haberman, MD. Instead, rheumatology patients should consult with their medical provider about their overall risk factors for COVID-19 and make plans accordingly, says Dr. Haberman, a clinical instructor in rheumatology in the Department of Medicine at NYU Langone.

Dr. Fernandez-Ruiz says the team now plans to test patients with lupus and patients with arthritis for coronavirus antibodies to see how many study participants were infected at some point and whether any were at greater or lesser risk of infection.

Funding support for the studies was provided by National Institutes of Health grants P50 AR07059, R01 AR074500, and T32 AR069515. Additional support was provided by Bloomberg Philanthropies COVID-19 Response Initiative Grants, The Riley Family Foundation, The Snyder Family Foundation, and Pfizers COVID-19 Competitive Grants Program.

Dr. Haberman and other study investigators have participated in other research projects sponsored by various manufacturers of arthritis drugs, as well as served on advisory boards to AbbVie, Amgen, Astrazeneca, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, GlaxoSmithKline, Janssen, Johnson & Johnson, Novartis, Pfizer, Sanofi, and UCB. All of these arrangements are being managed in accordance with the policies and practices of NYU Langone.

Besides Dr. Haberman and Dr. Fernandez-Ruiz, other NYU Langone researchers involved in the studies are co-lead investigators Mala Masson, Rochelle L. Castillo, MD, and Alan Chen; senior investigators Amit Saxena, MD, Peter M. Izmirly, MD, Samrachana Adhikari, PhD, and Jose U. Scher, MD; and co-investigators Allison Guttman, Philip Carlucci, Kristina Deonaraine, Michael Golpanian, Kimberly Robins, Miao Chang, H. Michael Belmont, MD, Jill P. Buyon, MD, Ashira Blazer, MD, Di Yan, and Deborah Ramirez. Additional study co-investigators are Mimi Kim at Albert Einstein College of Medicine in New York; and Benjamin Myers at Cornell University in Ithaca, New York.

David MarchPhone: 212-404-3528david.march@nyulangone.org

Read the rest here:
Most Adults with Lupus or Common Types of Arthritis Have Similar Risks of Getting Admitted to Hospital as Other Patients with COVID-19 - NYU Langone...

Disease-modifying antirheumatic drugs have reduced the need for total knee and hip arthroplasties (TKA and THA) in patients with rheumatoid arthritis (RA). However, there is still a far greater long-term risk of undergoing THA or TKA in patients with RA compared with patients who do not have RA, according to a study published in The Journal of Arthroplasty.

Since 1991 the proportion of patients with RA who are required to undergo TKA has dropped from 21.0% to as low as 2.4%. However, the few previous studies have been based on populations in the United States and Europe.

Patients with RA who experience joint destruction, intractable joint pain, or unacceptable functional decline usually require joint arthroplasty, the authors explained.

Researchers conducted a large-scale retrospective cohort study of 32,949 patients in Taiwan who were diagnosed with RA from 2000 to 2012. They were matched with 32,949 non-RA controls. Patients with RA had a more unfavorable Charlson comorbidity index score.

After adjusting for demographics and comorbidities, patients in the RA cohort had a 4.02-fold higher risk of undergoing TKA or THA (95% CI, 3.67-4.41). Factors that significantly increased the risk of THA or TKA were increasing age, living in an area of low urbanization, working as a manual laborer, 1 point in CCI score, having hypertension, or having gout.

Using multivariable stratified analyses, the researchers found that patients younger than 40 years actually had the highest risk of THA or TKA (adjusted hazard ratio, 43.18; 95% CI, 16.01-116.47). Careful interpretation of the results is needed because of relatively small sample size of this age interval, the authors noted.

However, they did note a previous study had shown young-onset RA was correlated with reduced radiographic progression and better functional score after 3 years. Those findings taken with the findings from the current study suggest that despite the better short-term outcome, patients with young-onset RA are still more at risk of undergoing TKA and THA compared with patients with late-onset RA, the authors wrote.

Based on the actual surgical procedures performed, patients with RA had a 4.56-fold higher risk of requiring THA, a 3.85-fold higher risk of TKA, and a 19.39-fold higher risk of requiring both THA and TKA compared with the non-RA cohort.

We recommend that future researchers can include more detailed documented dose or regimen of DMARDs utilization to verify the doseresponse effect in reducing the THA or TKA in RA patients, the authors concluded.

Reference

Lee Y-H, Ko P-Y, Kao S-L, Lin M-C, Cheng-Chung Wei J. Risk of total knee and hip arthroplasty in patients with rheumatoid arthritis: a 12-year retrospective cohort study of 65,898 patients. J Arthroplasty. Published online July 2, 2020. doi:10.1016/j.arth.2020.06.085

Go here to read the rest:
Understanding the Risk of Joint Replacement in Patients With Rheumatoid Arthritis - AJMC.com Managed Markets Network

Transparency Market Research (TMR) has published a new report titled, Joint Pain Injections Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, theglobal joint pain injections marketis expected to exceed a value of US$ 3 Bn by the end of 2018. The global market is anticipated to surpass US$ 6 Bn by 2026 and expand at a high single digit CAGR from 2018 to 2026. Rise in number of geriatric patients, increase in awareness regarding joint disorders, and high unmet medical needs are expected to augment the global market from 2018 to 2026. The joint pain injections market is projected to expand, owing to an increase in the prevalence of joint pain among the population, demand for better treatments, and development of healthcare infrastructure in various countries across the globe.

Increasing prevalence of arthritis and other bone-related disorders

According to facts published by Arthritis Foundation, arthritis is the leading cause of disability among adults in the U.S. Approximately 54 million adults and 300,000 babies and children in the U.S. suffer from arthritis or any rheumatic condition. More than 78 million people in the U.S. are likely to suffer from doctor-diagnosed arthritis by 2040. Furthermore, osteoarthritis is the most common type of arthritis and affects approximately 31 million people in the U.S. Increasing prevalence of arthritis further boosts the demand for disease modifying treatments, which in turn is anticipated to propel the joint pain injections market during forecast period.

Request Brochure of Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47664

Increase in prevalence of obesity leading to joint pain

Obesity is considered a risk factor for various joint disorders, especially related to knee, such as knee pain and knee osteoarthritis. According to the fact sheet published by World Health Organization (WHO), worldwide obesity has tripled since 1975. In 2016. 1.9 billion People were overweight and among them, more than 650 million adults were obese. Moreover, approximately 41 million children under the age of 5 were obese in 2016. According to the 2015-2016 National Health and Nutrition Examination Survey (NHANES), more than one in four children of Hispanic origin ages 2 to 19 had obesity, and approximately 47% of adults suffered from obesity. Increasing patient pool in developing countries as well as developed countries is estimated to propel healthcare spending for joint pain treatments in these countries and consequently, drive the joint pain injections market.

Request for Analysis of COVID-19 Impact on Joint Pain Injections Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=47664

High unmet needs in patients with joint pain

Arthritis is the most common cause of joint pain and a major cause of disability and impaired mobility among the population. Currently available treatment options are insufficient, as they primarily focus on symptom relief and pain mitigation. There are no drugs available that can cure, reverse, or halt disease progression such as osteoarthritis. Moreover, some patients are unable to find relief with available treatments and continue to suffer in pain; therefore, there are large unmet needs in patients with joint pain. This provides opportunity for advance treatment options in the joint pain injections market.

Hyaluronic acid injections segment dominates the global market due to increasing acceptance for the treatment of osteoarthritis

In terms of injection type, hyaluronic acid injections is a highly attractive segment of the global joint pain injections market, followed by corticosteroid injections and others segments. This is attributable to the effectiveness of hyaluronic acid injections in the treatment of knee osteoarthritis, where other treatments are contraindicated.According to rapid response report published by CADTH, viscosupplementation with hyaluronic acid in adults with knee osteoarthritis is superior to intra-articular placebo and other conventional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), in terms of improving knee pain and function with minimum adverse effects.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=47664

North America dominates the global market owing to high acceptance of viscosupplementation in the region

North America dominates the global joint pain injections market due to a large patient pool, increase in the geriatric population, increased obesity, and high acceptance of advanced treatments for the joint pain relief in the region. The region is estimated to maintain its dominance during the forecast period. Viscosupplementation with hyaluronic acid products is approved by US FDA for the treatment of knee osteoarthritis. Moreover, rising healthcare expenditure and increasing investments are key factors that are anticipated to boost the joint pain injections market in the next few years. The joint pain injections market in Asia Pacific is projected to expand at a notable CAGR due to increasing about join disorders in developing countries and rising research initiatives and manufacturing of hyaluronic acid products in Japan.

Buy Joint Pain Injections Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=47664&ltype=S

Investments by key players is driving the globaljoint pain injections market

Major players operating in the joint pain injections market include Allergan Plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Flexion Therapeutics, Inc., Zimmer Biomet Holdings, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

View original post here:
Joint Pain Injections Market: Investments by key players is driving the global market - BioSpace